|By Business Wire||
|June 10, 2014 11:00 AM EDT||
SomaLogic, Inc., announced today that the Perelman School of Medicine at the University of Pennsylvania is the first biomedical research center that will offer researchers on-site access to the SOMAscan™ assay, the most powerful proteomics platform available today. The assay will be performed at Penn’s Institute for Translational Medicine and Therapeutics (ITMAT), under the leadership of Daniel J. Rader, MD, associate director of ITMAT and chair of the Department of Genetics., and Stephen Master, MD, PhD, assistant professor of Pathology and Laboratory Medicine and director of ITMAT’s Translational Core Laboratory. It is expected that the SOMAscan assay will be fully functional at Penn by midsummer 2014.
“We are delighted that our first partner in bringing our powerful technology to more researchers is the University of Pennsylvania,” said Byron Hewett, Chief Executive Officer of SomaLogic. “The leadership of Dr. Rader and Dr. Master, together with the University’s reputation and skills in applying cutting-edge biotechnology tools to critical biomedical questions, will help ensure that this first non-SomaLogic center for our SOMAscan assay will be successful.”
SomaLogic's breakthrough SOMAscan proteomic assay efficiently, accurately, and rapidly identifies and quantifies 1,129 proteins across a wide range of concentrations in small volumes of multiple biological sample types. Compared to other current proteomic technologies, SomaLogic's breadth and depth of coverage offers unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. Until now, it has only been offered as a service through SomaLogic at its laboratories in Boulder, CO.
“SOMAscan is powerful technology that has the potential to enhance translational research in a number of ways. We are excited to be the first biomedical research center to make the assay more accessible to researchers and expect there to be a high demand, ” said Dr. Rader.*
“Our goal is to get this powerful tool into the hands of as many researchers as possible, as soon as possible,” said Hewett. “We anticipate announcing several additional centers over the next few months, and are carefully evaluating additional requests from many different research centers for SOMAscan placement at their respective institutions.”
The SOMAscan placement is the first under an agreement between Agilent Technologies and SomaLogic to expand access to the SOMAscan platform in research centers in addition to the commercial SOMAscan service offered directly by SomaLogic throughout the U.S. and internationally.
*Dr. Rader has no financial interest or other relationship with SomaLogic, apart from the scientific collaboration described here.
SomaLogic, Inc., is a privately held biomarker discovery and clinical diagnostics company based in Boulder, Colo. The company's mission is to use its proprietary modified aptamer-based proteomic technologies to develop a wide range of enhanced protein-analysis tools and reagents for the life sciences community, to facilitate biomarker discovery and validation for diagnostic and therapeutic applications, and to develop and commercialize clinical diagnostic products that will improve the delivery of health care by offering timely and accurate diagnostic information to physicians and their patients. Further information about SomaLogic can be found at www.somalogic.com.
Sep. 26, 2016 08:15 AM EDT Reads: 2,534
Sep. 26, 2016 08:15 AM EDT Reads: 1,541
Sep. 26, 2016 08:15 AM EDT Reads: 2,364
Sep. 26, 2016 07:15 AM EDT Reads: 1,879
Sep. 26, 2016 07:15 AM EDT Reads: 1,596
Sep. 26, 2016 07:00 AM EDT Reads: 2,646
Sep. 26, 2016 06:45 AM EDT Reads: 1,956
Sep. 26, 2016 06:45 AM EDT Reads: 1,075
Sep. 26, 2016 06:30 AM EDT Reads: 2,415
Sep. 26, 2016 06:30 AM EDT Reads: 1,569
Sep. 26, 2016 06:15 AM EDT Reads: 1,651
Sep. 26, 2016 04:30 AM EDT Reads: 1,060
Sep. 26, 2016 04:30 AM EDT Reads: 1,417
Information technology is an industry that has always experienced change, and the dramatic change sweeping across the industry today could not be truthfully described as the first time we've seen such widespread change impacting customer investments. However, the rate of the change, and the potential outcomes from today's digital transformation has the distinct potential to separate the industry into two camps: Organizations that see the change coming, embrace it, and successful leverage it; and...
Sep. 26, 2016 03:15 AM EDT Reads: 1,092
There is growing need for data-driven applications and the need for digital platforms to build these apps. In his session at 19th Cloud Expo, Muddu Sudhakar, VP and GM of Security & IoT at Splunk, will cover different PaaS solutions and Big Data platforms that are available to build applications. In addition, AI and machine learning are creating new requirements that developers need in the building of next-gen apps. The next-generation digital platforms have some of the past platform needs a...
Sep. 26, 2016 03:00 AM EDT Reads: 1,770